Sickle cell disease (SCD) is a life-threatening hereditary blood disorder that affects millions
of people worldwide, especially in sub-Saharan Africa. This condition has a multi-organ …

Background Sickle cell disease (SCD) is a genetic hemoglobinopathy with an incidence of
250–300,000 births per year worldwide. SCD leads to a diffuse vasculopathy which …

Sickle cell disease (SCD) is a genetic hemoglobinopathy associated with extensive
morbidity and early mortality. While there have been recent improvements in available …

Hydroxyurea (HU) is commonly used as a treatment for patients with sickle cell disease
(SCD) to enhance fetal hemoglobin production. This increased production is expected to …

Children with sickle cell disease (SCD) have an increased risk of sleep disordered breathing
(SDB) compared with the general pediatric population. There has been a growing research …

Introduction Sickle cell disease (SCD) is an inherited hemoglobinopathy characterized by
the production of sickle hemoglobin, leading to red blood cells sickling and hemolysis in …

Sickle cell disease (SCD) is an hemoglobinopathy resulting in the production of an
abnormal Hb (HbS) which can polymerize in deoxygenated conditions, leading to the …

OBJECTIVES: Malignant pertussis, the most severe manifestation of Bordetella pertussis
infection, is characterized by multiple organ failure and a high mortality rate despite …

Background and objective Sickle cell disease (SCD) is a very common autosomal recessive
hemoglobinopathy leading to multiple pulmonary complications that are closely associated …

Objective To evaluate the acceptability and safety profile of nocturnal long-term oxygen
therapy (LTOT) in children with sickle cell disease (SCD) and chronic hypoxaemia. Design …